Nuvectis Pharma Announced 33% Response Rate And 100% Disease Control Rate Observed In Patients Evaluated For Efficacy From The NXP800 Phase 1b Clinical Trial In Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma 宣佈,對鉑耐藥 ARID1A 突變卵巢癌的 NXP800 1b 期臨床試驗療效進行評估的患者中,觀察到的反應率爲 33%,疾病控制率爲 100%